Drug Design V

Drug design continues to be an increasingly essential, whilst expensive challenge for the pharmaceutical and biotechnology industry. Recent advances in the field, including computational chemistry, combinational chemistry and pharmacognosy, may have the ability to overcome the shortcomings of conventional techniques and revolutionise drug design methodologies. Already we have seen considerable improvements in drug potency and specificity having a huge commercial impact worldwide.

SMi’s ‘Drug Design V’ will address how both the pharmaceutical and biotechnology industries can identify early failures whilst increasing the number of potential hits quicker and faster with new techniques being made available. This event will bring together high level industry representatives to discuss in detail the latest improvements in the field of drug design. Key issues to be discussed include QSAR, pharmacognosy, and ADME/TOX, whilst also focussing on new ways to use existing methods such as structure based drug design, virtual screening and library design to ensure the greatest success possible.

 Speakers at this event include:

• Dr Joseph Bolen, Senior Vice President, Discovery, Millennium
• Dr Jeffrey Wiseman, Vice President & Officer, Technology & Informatics, Locus Pharmaceuticals
• Dr Jonathan Mason, Executive Director, Medicinal Informatics Structure & Design, Pfizer
• Dr Alexander Alex, Director, Pfizer
• Dr Michael Hennig, Vice Director, Molecular Structure Research, F. Hoffmann-La Roche
• Dr Philip Jewsbury, Associate Director, Computational Chemistry, AstraZeneca